Nicolas Sayegh

List of Publications by Year
in descending order

33	206	1307594 7	1125743 13
papers	citations	h-index	g-index

33	33	33	70
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axisâ€“Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. European Urology Focus, 2023, 9, 106-109.	3.1	3
2	Recent Advances in the Management of Metastatic Prostate Cancer. JCO Oncology Practice, 2022, 18, 45-55.	2.9	75
3	Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. Clinical Genitourinary Cancer, 2022, , .	1.9	3
4	Editorial Comment. Journal of Urology, 2022, , 101097JU0000000000000242501.	0.4	0
5	Survival outcomes and characterization of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT) who do not achieve an optimal PSA response (PSA â‰¤0.2 ng/mL).. Journal of Clinical Oncology, 2022, 40, 123-123.	1.6	1
6	Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing intensified androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2022, 40, 133-133.	1.6	0
7	Tumor genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation (UCS) compared to pure urothelial carcinoma (UC).. Journal of Clinical Oncology, 2022, 40, 553-553.	1.6	0
8	Tumor genomic landscape in younger compared to older patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2022, 40, 373-373.	1.6	0
9	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study.. Journal of Clinical Oncology, 2022, 40, 162-162.	1.6	0
10	Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer.. Journal of Clinical Oncology, 2022, 40, 561-561.	1.6	0
11	Genomic characterization of patients (pts) with de-novo high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) compared to those without dn-hv-mCSPC.. Journal of Clinical Oncology, 2022, 40, 186-186.	1.6	0
12	Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.. Journal of Clinical Oncology, 2022, 40, 336-336.	1.6	1
13	Characterization of aberrant alternative splicing landscape in patients with renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2022, 40, 386-386.	1.6	1
14	Overall survival (OS) after progression on first novel hormonal therapy (NHT) in patients (pts) with metastatic castration-sensitive versus castration-resistant prostate cancer (mCSPC versus mCRPC).. Journal of Clinical Oncology, 2022, 40, 121-121.	1.6	0
15	Tumor genomic landscape in smokers compared to non-smoker patients with locally advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2022, 40, 554-554.	1.6	0
16	HSR22-151: Access to Care and Health Care Quality Metrics in Urban Versus Rural Patients With Advanced Genitourinary Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, HSR22-151.	4.9	0
17	Development of Novel Regimens Combining Immune Checkpoint Inhibitors and Radiation Therapy in Prostate Cancer. European Urology, 2022, 81, 263-265.	1.9	0
18	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 2022, 5, e225394.	5.9	37

#	Article	IF	Citations
19	Targeting Cardiovascular Adverse EventsÂof Metastatic Renal Cell Carcinoma Therapies. JACC: CardioOncology, 2022, 4, 235-237.	4.0	1
20	Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal of Cancer, 2022, 171, 124-132.	2.8	14
21	Body composition and metastatic prostate cancer survivorship. Cancer Treatment and Research Communications, 2021, 27, 100322.	1.7	6
22	Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA).. Journal of Clinical Oncology, 2021, 39, 256-256.	1.6	0
23	Urodynamics in patients with multiple sclerosis: is it necessary? A randomized-controlled trial. Scandinavian Journal of Urology, 2021, 55, 161-168.	1.0	1
24	Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.. Journal of Clinical Oncology, 2021, 39, 135-135.	1.6	1
25	Association of circulating tumor cells (CTC) with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort.. Journal of Clinical Oncology, 2021, 39, 59-59.	1.6	0
26	Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations.. Journal of Clinical Oncology, 2021, 39, 166-166.	1.6	0
27	Seeing the forest for the treesâ€"single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer. Cancer Cell, 2021, 39, 594-596.	16.8	21
28	Correlation of baseline circulating tumor cells (CTC) and associated genomic profile with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort.. Journal of Clinical Oncology, 2021, 39, 5077-5077.	1.6	0
29	Identification of Somatic Gene Signatures in Circulating <scp>Cell-Free DNA</scp> Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist, 2021, 26, 751-760.	3.7	9
30	Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations. European Urology Oncology, 2021, 4, 553-557.	5.4	0
31	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. Cancers, 2021, 13, 4951.	3.7	19
32	Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist, 2021, 26, 1006-e2129.	3.7	13
33	Abstract P012: Genomic and clinical correlates of overall survival (OS) in men with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT). , 2021, , .		0